test

Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer

Conditions

Colon | Liver | Rectum

What is the purpose of this trial?

The objective of this study is to evaluate and compare the efficacy and safety of regorafenib vs. placebo in subjects with colorectal cancer after curative resection of liver metastasis and completion of all planned chemotherapy.


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Bayer Healthcare Pharmaceuticals, Inc.
Dates:
07/23/2014
Last Updated:
Study HIC#:
1402013496